NCT00986986View on ClinicalTrials.gov

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
HIV InfectionsDyslipidemiaEndothelial Dysfunction
Interventions
DRUG

extended release niacin

Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.

Trial Locations (1)

96816

University of Hawaii - Hawaii Center for AIDS, Honolulu

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Hawaii

OTHER

NCT00986986 - Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels | Biotech Hunter | Biotech Hunter